![]() |
市场调查报告书
商品编码
1847177
美国输液治疗设备市场:市场规模、份额和趋势分析(2026-2032 年)Infusion Therapy Market Size, Share & Trends Analysis | United States | 2026-2032 | Includes: Irrigation Solutions, Drug Reconstitution, and 3 more |
||||||
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
预计到2025年,美国输液治疗设备市场规模将超过41亿美元。预计到2031年,该市场将以2.3%的复合年增长率成长,超过48亿美元。
本报告涵盖输液帮浦、输液器、无针接头、三通阀、静脉过滤器和输血装置。报告量化了产品数量、平均售价、市场价值、成长率和企业市场占有率。此外,报告还分析了成长驱动因素、近期併购活动、召回事件和技术趋势。报告提供截至2024年的历史数据,并预测至2031年。
它反映了医疗系统如何评估医院、专科诊所、门诊手术中心、家庭输液联网智慧帮浦、药物库、减少管理错误软体和 EMR互通性。
市场概览
医院和医疗网路正在从传统的资本更新周期转向完全连网的输液平台。
这些平台结合了药物库、管理错误减少软体和即时 EMR通讯,实现了自动化程式设计和文件记录。
这种转变增加了前期成本,并增加了软体授权、分析、网路安全、介面检验、培训和药物库管治等方面的持续支出。由于安全更新和新功能依赖于支援的硬体和软体基准,因此系统更新的频率也比以往更高。
因此,即使销售量成长不大,由于平均售价、订阅费和付费服务的成长,市场价值也将上升。从长远来看,企业采购决策正在转变,优先考虑标准化泵浦组、系统整合和资料服务,而不是一次性设备采购。
市场驱动因素
智慧型输液帮浦和互通性。减少给药误差、标准化药物库以及双向电子病历集成,可提高安全性和工作流程效率。这些功能需要检验的介面和管治,从而提高平均售价和服务收入。
感染预防 - 医院承担导管相关血流感染的成本,这促使医院采用用于感染预防的高级设备和耗材,包括分离隔膜连接器、中性位移设计和抗菌选项。
其他照护场所-家庭输液和其他非急性照护在医疗服务中所占比例越来越高。这些场所的采购较为分散,通常无法从集团采购组织 (GPO) 获得折扣,因此价格较高。
生命週期和网路安全 - 定期的安全性修补程式、召回和功能发布加快了更换週期,并保持产品平臺活跃。
临床生产力——一个简化药物库管理、警报缓解、车队监控和分析的平台,帮助大型医疗保健系统安全精益地运营,从而增强了网路升级的必要性。
市场限制
不利事件和召回 - 安全问题,包括泵召回,扰乱运营,给库存带来压力,并提高新安装的实质审查阈值。
非器材竞争-新药和非侵入性治疗方法可能在某些适应症中取代器材的使用。例如,长效局部止痛药在周边神经阻断途径的应用降低了对某些抛弃式门诊镇痛帮浦的需求。
集团采购组织 (GPO) 集中需求并协商更低的价格,这可能会限制小型製造商进入市场,并减缓新设备的采用。
证据缺口-由于缺乏结果证据,某些高级功能(例如某些连接器上的抗菌涂层)的成长速度将会放缓。
价格压力-成熟的竞争格局和合约週期意味着,即使软体和服务不断扩张,某些类别的价格上涨幅度也较为温和。
目标市场和数据范围
定量范围
市场规模、市占率、市场预测、成长率、销售量、平均售价
定性范围
成长趋势、限制因素、竞争对手竞争分析及SWOT分析、併购、公司简介及产品系列、FDA召回、颠覆性技术、疾病概述,这些因素共同影响输液治疗的需求。
时期
基准年:2025年,预测期间:2026-2032年,历史资料:2022-2024年
数据来源
对产业领导者的初步访谈、政府医师资料、监管资料、私人医院资料、进出口资料、iData Research 内部资料库。
方法
收入模型为单位销售量乘以平均售价,透过程序和使用率输入检验,并与泵浦和设备的安装基础和更换假设进行核对。
治疗地点
医院、专科诊所、门诊手术中心及居家医疗
目标市场及区隔
输液帮浦市场
单元分析适用于大容量帮浦和注射式帮浦。
输液器市场(IV 套装)
水泵组
重力组和辅助组
按材质分类的扩展套装。 DEHP 套装和非 DEHP 套装。
无针连接器市场
止水阀市场
静脉输液过滤器市场
输血器市场
输血加温器市场
竞争分析
2025 年,贝克顿·迪金森公司在美国输液治疗设备和耗材市场占据领先地位。收购 CareFusion 后,该公司扩大了在输液设备领域的地位,并在输液器和无针连接器领域获得了领先地位。
ICU Medical是第二大竞争对手,在输液帮浦、输液器和无针接头领域拥有强大的市场份额,并在三通阀领域占据领先地位。 2022年收购Smiths Medical后,该公司已做好充分准备,进一步拓展产品线。
百特在输液帮浦、输液器、无针接头、三通阀和输血器领域拥有广泛的市场份额,位居第三。虽然该公司并非细分市场的领导者,但凭藉其庞大的分销网络,百特的产品能够触及众多医疗服务提供者。
其他参与企业则活跃于特定产品或医疗领域。
这是一个高度集中的市场,有利于对品质、软体和服务进行持续投资,同时也提高了新进入者的门槛。
科技与临床趋势
药物库和剂量误差减少是大规模部署的标准要求。
中性或最小反流连接器价格较高,因为人们认为它们发生血液逆流和阻塞的风险较低。
抗菌或可消毒设计在证据和工作流程支持其价值的情况下正获得越来越多的支持。
警报和分析用于减少误报、发现培训差距和规划维护。
家庭输液物流和报销持续扩大,市场在急性和非急性环境中仍保持多元化。
地区
本报告涵盖美国。
美国输液治疗设备市场中规模最大、成长最快的细分市场是什么?在预测期内,哪些类别可能获得最大的市占率?
输液治疗设备市场与更广泛的经济和医院管理有何关係?包括整合、网路安全支出以及向标准化和企业平台的转变?
未来哪些因素将影响市场格局,包括电子病历互通性、减少管理错误、感染预防、召回、证据要求、集团采购组织合约以及替代医疗场所的兴起?
智慧型帮浦、药物库和自动编程将如何改变更换週期?这将对定价、订阅和付费服务产生什么影响?
根据感染风险、消毒效果和易用性,连接器、组件和旋塞等产品设计中哪些正在获得市场认可?
召回和不利事件报告如何影响医疗机构的采购决策和供应商选择。
供应商如何透过将安全功能、警报管理和分析与临床生产力和成本控制联繫起来,来加强其商业案例。
商业团队应该如何规划家庭输液的成长、分散的采购以及 GPO 合约以外的定价策略?
成长面临的主要风险是什么?例如,非器械疗法是否会减少某些治疗途径中器械的使用?
iData Research 的《美国输液治疗设备市场报告》透过流程感知模型、企业市场占有率分析和定价详情来回答这些问题。
这份报告可用于按类别量化需求、规划产品蓝图、设定定价和合约目标,以及优先考虑能够加速产品普及的培训和支援计画。
目录
图表清单
图表列表
美国输液治疗设备市场概览
竞争分析
新兴市场与技术
市场趋势
市场趋势
市场区隔
重要报告更新
版本历史记录
调查方法
全球关税的影响
美国输液治疗设备市场概览
输液帮浦市场
输液器市场
无针连接器市场
止水阀市场
静脉输液过滤器市场
输血设备市场
输血加温器市场
The U.S. infusion therapy device market was valued at over $4.1 billion in 2025. The market is expected to grow at a 2.3 percent CAGR to exceed $4.8 billion by 2031.
This report covers infusion pumps, infusion sets, needleless connectors, stopcocks, intravenous filters, and devices used for blood transfusion. It quantifies units, average selling prices, market values, growth rates, and company shares, and it analyzes growth drivers and limiters, recent M&A, recalls, and technology trends. It provides historical data to 2024 and forecasts to 2031.
The scope reflects how health systems evaluate networked smart pumps, drug libraries, dose-error reduction software, and EMR interoperability across hospitals, specialty clinics, ambulatory surgical centers, and home infusion.
Market Overview
Hospitals and health networks are moving from legacy capital replacement cycles toward fully networked infusion platforms.
These platforms combine drug libraries, dose-error reduction software, and real-time EMR communication for auto programming and auto documentation.
This shift increases upfront costs and adds ongoing fees for software licensing, analytics, cybersecurity, interface validation, training, and drug-library governance. Because security updates and new features depend on supported hardware and software baselines, fleets are refreshed more often than in the past.
As a result, market value rises through higher ASPs, subscriptions, and paid services, even when unit growth is modest. Over time, purchasing is becoming an enterprise decision that favors standardized pump fleets, system integration, and data services rather than one-off device buys.
Market Drivers
Smart pumps and interoperability. Dose-error reduction, standardized drug libraries, and bidirectional EMR integration improve safety and workflow. These features require validated interfaces and governance, which supports higher ASPs and service revenues.
Infection prevention. Hospitals carry the cost of catheter-related bloodstream infections. This drives adoption of premium infection-prevention devices and consumables, including split septum connectors, neutral displacement designs, and antimicrobial options where evidence supports use.
Alternate care sites. Home infusion and other non-acute settings are a rising share of therapy. Purchasing in these settings is fragmented and often has fewer GPO discounts, which supports higher price realization.
Lifecycle and cybersecurity. Regular security patches, recalls, and feature releases accelerate replacement cycles and keep product pipelines active.
Clinical productivity. Platforms that simplify drug-library management, alarm reduction, fleet monitoring, and analytics help large health systems run safer and leaner, which strengthens the case for networked upgrades.
Market Limiters
Adverse events and recalls. Safety issues, including pump recalls, disrupt operations and strain inventory. They also raise due diligence thresholds for new placements.
Non-device competition. New drugs and non-invasive therapies can displace device usage in select indications. An example is long-acting local analgesia in peripheral nerve block pathways, which reduced demand for some disposable ambulatory pain pumps.
Group purchasing organizations. GPOs aggregate demand and negotiate lower prices, which can limit market access for smaller manufacturers and can slow adoption of novel devices.
Evidence gaps. Some premium features, such as antimicrobial coatings on certain connectors, face slower growth where outcome evidence is limited.
Pricing pressure. A mature competitive field and contract cycles keep price gains moderate in several categories, even as software and services expand.
Market Coverage and Data Scope
Quantitative coverage
Market size, market shares, market forecasts, growth rates, units sold, and average selling prices.
Qualitative coverage
Growth trends, limiters, competitive analysis and SWOT for top competitors, mergers and acquisitions, company profiles and product portfolios, FDA recalls, disruptive technologies, and disease overviews that shape demand for infusion therapy.
Time frame
Base year 2025, forecasts 2026 to 2032, historical data 2022 to 2024.
Data sources
Primary interviews with industry leaders, government physician data, regulatory data, hospital private data, import and export data, and the iData Research internal database.
Method note
Revenue is modeled from units multiplied by ASP, validated with procedure and utilization inputs, and checked against installed base and replacement assumptions for pumps and sets.
Care settings
Hospitals, specialty clinics, ambulatory surgical centers, and home care.
Markets Covered and Segmentation
Infusion Pump Market
Unit analysis applies to large volume and syringe pumps.
Intravenous Set Market (IV sets)
Pump sets.
Gravity sets and secondary sets.
Extension sets by material. DEHP sets and non-DEHP sets.
Needleless Connector Market
Stopcock Market
Intravenous Filter Market
Blood Transfusion Set Market
Blood Warmer Market
Competitive Analysis
Becton Dickinson led the U.S. infusion therapy device and consumables market in 2025. The company expanded its position in IV devices after acquiring CareFusion and holds leadership in IV sets and needleless connectors.
ICU Medical was the second-largest competitor with strong shares in infusion pumps, IV sets, and needleless connectors, and leadership in stopcocks. After acquiring Smiths Medical in 2022, the company is positioned for further product activity.
Baxter ranked third in total share with a broad presence in infusion pumps, IV sets, needleless connectors, stopcocks, and blood transfusion sets. The company is not the segment leader but maintains wide access across provider types through an extensive distribution network.
Other participants are active in selected products or care settings.
This is a concentrated market that supports sustained investment in quality, software, and services and that also raises the bar for new entrants.
Technology and Practice Trends
Drug libraries and dose-error reduction are standard requirements in large placements.
Neutral or minimal reflux connectors command a premium due to lower perceived risk of blood reflux and occlusion.
Antimicrobial or disinfectable designs gain traction where evidence and workflow support the value case.
Alarm and analytics features are used to reduce nuisance alarms, find training gaps, and plan maintenance.
Home infusion logistics and reimbursement continue to expand, which keeps the market diverse across acute and non-acute buyers.
Geography
This edition covers the United States.
Where is the largest and fastest growing opportunity within U.S. infusion therapy devices and which categories are most likely to gain share over the forecast period.
How does the infusion therapy device market relate to the broader economy and to hospital operations, including consolidation, cybersecurity spending, and the shift toward standardization and enterprise platforms.
What forces will shape the market going forward, including EMR interoperability, dose-error reduction, infection prevention, recalls, evidence requirements, GPO contracts, and the rise of alternate care sites.
How do smart pumps, drug libraries, and auto programming change replacement cycles and what are the implications for pricing, subscriptions, and paid services.
Which product designs are gaining traction in connectors, sets, and stopcocks based on infection risk, disinfection profiles, and ease of use.
What is the impact of recalls and adverse event reporting on provider purchasing decisions and vendor selection.
How can suppliers make a stronger business case by linking safety features, alarm management, and analytics to clinical productivity and cost control.
How should commercial teams plan for home infusion growth, fragmented purchasing, and pricing strategies outside GPO contracts.
Where are the key risks to growth, including non-device therapies that reduce device usage in specific pathways.
The U.S. infusion therapy device market report from iData Research answers these questions with procedure-aware models, company share analysis, and pricing detail.
Use it to quantify demand by category, plan product roadmaps, set pricing and contracting targets, and prioritize training and support programs that speed adoption.
Table Of Contents
List Of Figures
List Of Charts
U.S. Infusion Therapy Device Market Overview
Competitive Analysis
Emerging Markets And Technologies
Market Trends
Market Developments
Market Segmentation
Key Report Updates
Version History
Research Methodology
Impact Of Global Tariffs
U.S. Infusion Therapy Device Market Overview
Infusion Pump Market
Intravenous Set Market
Needleless Connector Market
Stopcock Market
Intravenous Filter Market
Blood Transfusion Device Market
Blood Warmer Market
Figure 9-8 Other Blood Transfusion Device Market, U.S., 2022 - 2032